MARKET

VCEL

VCEL

Vericel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

52.65
-0.45
-0.85%
Closed 16:54 05/07 EDT
OPEN
54.19
PREV CLOSE
53.10
HIGH
54.98
LOW
52.42
VOLUME
434.27K
TURNOVER
--
52 WEEK HIGH
64.90
52 WEEK LOW
12.82
MARKET CAP
2.43B
P/E (TTM)
1076.69
1D
5D
1M
3M
1Y
5Y
Tissue Regeneration Market to Register Incremental Revenue Opportunities During the Forecast Period 2021-2027
May 07, 2021 (Heraldkeepers) -- The Global Tissue Regeneration Market is segmented on the lines of its technology, treatment, application and regional. Based...
Heraldkeepers · 2d ago
Global $6.56 Billion Regenerative Medicine for Cartilage Markets, 2015-2020, 2020-2025F, 2030F
GlobeNewswire · 3d ago
HC Wainwright & Co. Maintains Buy on Vericel, Raises Price Target to $65
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Vericel (NASDAQ:VCEL) with a Buy and raises the price target from $60 to $65.
Benzinga · 3d ago
--HC Wainwright Adjusts Price Target on Vericel to $65 From $60, Maintains Buy Rating
MT Newswires · 3d ago
Analysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Pfizer (PFE)
Analysts fell to the sidelines weighing in on Vericel (VCEL) and Pfizer (PFE) with neutral ratings, indicating that the experts are neither bullish nor
SmarterAnalyst · 4d ago
BTIG Believes Vericel (VCEL) Still Has Room to Grow
BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel (VCEL) today and set a price target of $63.00. The company's shares closed last Wednesday
SmarterAnalyst · 4d ago
Vericel (VCEL) Gets a Hold Rating from Oppenheimer
In a report released today, Kevin DeGeeter from Oppenheimer assigned a Hold rating to Vericel (VCEL). The company's shares closed last Wednesday at
SmarterAnalyst · 4d ago
Vericel Corporation (VCEL) Reports Q1 Loss, Tops Revenue Estimates
Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 8.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VCEL. Analyze the recent business situations of Vericel through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VCEL stock price target is 66.38 with a high estimate of 70.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 253
Institutional Holdings: 55.63M
% Owned: 120.69%
Shares Outstanding: 46.09M
TypeInstitutionsShares
Increased
50
4.35M
New
44
3.15M
Decreased
56
3.70M
Sold Out
10
654.93K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Non-Executive Chairman/Independent Director
Robert Zerbe
President/Chief Executive Officer/Director
Dominick Colangelo
Chief Financial Officer/Treasurer
Joseph Mara
Chief Operating Officer
Michael Halpin
Chief Accounting Officer/Vice President/Controller
Sandra Pennell
Vice President/General Counsel/Secretary
Sean Flynn
Other
Jonathan Hopper
Independent Director
Kevin McLaughlin
Independent Director
Steven Gilman
Independent Director
Heidi Hagen
Independent Director
Kevin Mclaughlin
Independent Director
Alan Rubino
Independent Director
Paul Wotton
No Data
About VCEL
Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Webull offers kinds of Vericel Corp stock information, including NASDAQ:VCEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VCEL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VCEL stock methods without spending real money on the virtual paper trading platform.